title: [Biologic therapy in idiopathic inflammatory myopathy].
abstract: The aim of this article is to study the evidence-based knowledge related to the use of biological therapies in patients diagnosed with idiopathic inflammatory myopathy (dermatomyositis, polymyositis and inclusion body myositis). In this review the leading published studies related to the use of biological therapy in patients with myositis are analysed; mainly those with high methodological standards, that means randomized and controlled studies. Methodological drawbacks due to the rarity and heterogeneity of these complex diseases are also addressed. Up to now is not possible to ascertain the biologics as a recommended therapy in patients with myositis, at least based in the current evidence-based knowledge, although it can not be neglected as a therapeutic option in some clinical situations, taking into account the scarce of effective treatments in those patients, especially in refractory myositis. Future studies probably will help to better define the role of biological therapies in patients with idiopathic inflammatory myopathy.
authors.affiliation: Servicio de Medicina Interna, Hospital General Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España. Electronic address: aselva@vhebron.net.
authors.forename: Albert
authors.initials: A
authors.lastname: Selva-O'Callaghan
authors.affiliation: Laboratorio de Enfermedades Autoinmunes Josep Font, CELLEX-IDIBAPS, Servicio de Enfermedades Autoinmunes, Institut Clínic de Medicina i Dermatologia (ICMiD), Hospital Clínic, Barcelona, España.
authors.forename: Manel
authors.initials: M
authors.lastname: Ramos Casals
authors.affiliation: Grup de Recerca Muscular, Hospital Clínic, Institut D'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) y Fundació CELLEX, Universitat de Barcelona, Barcelona, España.
authors.forename: Josep M
authors.initials: JM
authors.lastname: Grau Junyent
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D018951:Antigens, CD20; D001691:Biological Therapy; D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards; D004311:Double-Blind Method; D019317:Evidence-Based Medicine; D006801:Humans; D007388:Internal Medicine; D058990:Molecular Targeted Therapy; D015337:Multicenter Studies as Topic; D009220:Myositis / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D012955:Societies, Medical; D013030:Spain; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018951:Antigens, CD20; D014409:Tumor Necrosis Factor-alpha
keywords: Biologic therapy; Idiopathic inflammatory myopathy; Miopatía inflamatoria idiopática; Miositis; Myositis; Terapia biológica